Omnicare's Specialty Care Group Advanced Care Scripts (ACS) to Provide Specialty Pharmacy Services for Novartis' Farydak®
(Thomson Reuters ONE) -
CINCINNATI, March 5, 2015 - Advanced Care Scripts (ACS), a leading specialty
pharmacy and clinical services platform of Omnicare Specialty Care Group (SCG),
is proud to be part of the limited distribution network for the Novartis drug
Farydak® (panobinostat).
The US Food and Drug Administration (FDA) recently approved Farydak® capsules in
combination with bortezomib and dexamethasone for the treatment of patients with
multiple myeloma who have received at least two prior regimens, including
bortezomib and an immunomodulatory (IMiD) agent.
Multiple myeloma is an incurable blood cancer, and there is an urgent need for
new treatments. Farydak is approved under FDA's accelerated approval program;
regulatory applications are underway in the EU, Japan and worldwide. "We look
forward to providing our clinical services expertise in oncology to patients
prescribed this treatment option, and appreciate the opportunity to be part of
this limited distribution network," said Dennis Wilson, VP & General Manager of
Advanced Care Scripts.
Farydak has been shown to extend the progression-free survival (PFS) benefit of
the standard-of-care therapy in this patient population. Farydak is approved
under an accelerated approval based on PFS. Continued approval for this
indication may be contingent upon verification and description of clinical
benefit in confirmatory trials. The FDA's accelerated approval program gives
patients access to treatments for serious or life-threatening illnesses that
provide meaningful therapeutic benefit over existing treatments. The FDA has
approved a risk evaluation and mitigation strategy (REMS) for Farydak. The REMS
program serves to inform and educate healthcare professionals about the risks
that may be associated with Farydak treatment.
The goal of Advanced Care Scripts is to remove barriers to access and increase
speed to therapy. ACS has proven experience in successfully managing and
dispensing specialty medications, such as Farydak, and related clinical services
to improve adherence to therapy and patient outcomes.
About Omnicare Specialty Care Group
Omnicare Specialty Care Group (SCG) is a division of Omnicare, Inc., a Fortune
500 company and provider of comprehensive pharmaceutical services based in
Cincinnati, Ohio. Omnicare SCG is a combination of synergistic tenured companies
with a focused approach to pharmaceutical brand solutions. Together, Omnicare
SCG brings specialists in reimbursement methods, clinicians practiced in
medication therapy management for chronic disease states, and distribution
channel expertise. Solutions are tailored to drive product access by solving
challenges faced by patients and their caregivers, physicians, payers and
manufacturers. Custom programs are led by a single management team across the
organizational platforms, allowing coordination of resources and assets to
support positive outcomes for our patients. For more information, visit
www.omnicarescg.com.
About Advanced Care Scripts
Advanced Care Scripts, a specialty pharmacy, manages and dispenses specialty
medications and products nationwide. It coordinates services beginning with the
prescriber to simplify reimbursement and delivery of biotech therapies used to
treat cancer, infectious diseases, auto-immune disorders, multiple sclerosis,
hemophilia, and other disease states. Its customer service and comprehensive
patient care model provides compliance and adherence support and cost-effective
solutions for all classes of specialty medications.
# # #
Contact:
Patrick C. Lee
(513) 719-1507
patrick.lee(at)omnicare.com
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Omnicare via GlobeNewswire
[HUG#1899546]
Unternehmensinformation / Kurzprofil:
Datum: 05.03.2015 - 13:45 Uhr
Sprache: Deutsch
News-ID 376499
Anzahl Zeichen: 4589
contact information:
Town:
Covington, KY
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 169 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Omnicare's Specialty Care Group Advanced Care Scripts (ACS) to Provide Specialty Pharmacy Services for Novartis' Farydak®"
steht unter der journalistisch-redaktionellen Verantwortung von
Omnicare (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
